Ancora Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Ancora Advisors’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,245	Closed	-$118K	–	1983
2022 Q4	$118K	Buy	12,245 +5,000	+69%	+$44.2K	﹤0.01%	789
2022 Q3	$59K	Buy	7,245 +1,245	+21%	+$8.55K	﹤0.01%	1032
2022 Q2	$33K	Hold	6,000	–	–	﹤0.01%	1296
2022 Q1	$34K	Hold	6,000	–	–	﹤0.01%	1400
2021 Q4	$26K	Hold	6,000	–	–	﹤0.01%	1493
2021 Q3	$57K	Buy	+6,000	New	+$45K	﹤0.01%	1146

Other funds holding FENC

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Ancora Advisors's FENC Position: Q1 2023 in Review

Ancora Advisors sold out of Fennec Pharmaceuticals (FENC) in Q1 2023, closing a stake of 12,245 shares — an estimated $118K sold.

Ancora Advisors first reported a position in FENC in Q3 2021 and held it in 6 quarters. The position peaked at $118K in Q4 2022. 53 funds tracked by Wall St. Rank hold FENC as of Q1 2023.

Ancora Advisors reported no remaining Fennec Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Ancora Advisors sold 12,245 Fennec Pharmaceuticals shares in Q1 2023, an estimated $118K.
Ancora Advisors first reported a position in Fennec Pharmaceuticals in Q3 2021 and held it in 6 quarters.
Ancora Advisors's Fennec Pharmaceuticals position peaked at $118K in Q4 2022.
53 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2023.

Based on Ancora Advisors's 13F filing for Q1 2023, filed 16 May 2023.